Gabapentin for visual hallucinations
Researchers are testing whether gabapentin affects seeing things that are not there in people with Parkinson's.
Testing a treatment or activity · Study reference: TCTR20181220008
Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓
This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.
Open the official registry record ↗Follow this study
Looking for volunteers
- Start (reported date)
- 2019-01-02
- Study finished (reported date)
- 2020-12-31
Planned dates can move. A study finishing does not tell us when a paper will be published.
No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.
Changes we have recorded
- 2026-10-11 — recruiting
These are dates we observed a change, not necessarily the dates it happened.
Papers connected to this study
No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.
Who can join?
Ages 40 years to 90 years · Ask the team who can join
These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.
Read all the rules for taking part
Sex eligibility reported by registry: both
Full study name & original research details
Official study title
Gabapentin for the treatment of visual hallucination associated with Parkinson's disease
Original description
Conditions reported: Parkinson's disease Parkinson's disease, Visual hallucinations, Gabapentin, Quetiapine;Parkinson's disease, Visual hallucinations, Gabapentin, Quetiapine
Registry records for this study
Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.
- TCTR · TCTR20181220008 ↗ — Recruiting; WHO ICTRP processed 2026-08-03; checked 2026-10-13
- Study type
- Interventional
- Interventions
- -The patients was randomized to gabapentin for 4 weeks -The dose of gabapentin depend on body weight, if BW less than 50 kg titrate dose up to 300 mg/day, if BW equal or more than 50 mg titrate dose up to 600 mg/day,The patients was randomized to quetiapine for 4 weeks -The dose of quetiapine depend on body weight, if BW less than 50 kg titrate dose up to 50 mg/day, if BW equal or more than 50 mg titrate dose up to 75 mg/day;Active Comparator Drug,Active Comparator Drug;Gabapentin,Quetiapine
- Phases
- N/A
- Sponsor
- Research and Development Center
- Start date reported by registry
- 2019-01-02 (reported)
Registry updated: Not reported · Status last verified by the registry submitter: Not reported
Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.
Contact the research team
Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.
Chumpol Anamnart · 0814306100 · tom_ppk@yahoo.com
Study locations
Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.
Facility not reported
Thailand
Status not reportedThe original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.